Cd4 - Cd4 molecule Gene
Also Known as p55; W3/25
Species: Rattus norvegicus
Gene Type: protein coding
Gene ID: 24932
Summary
Enables immunoglobulin binding activity; protein tyrosine kinase binding activity; and signaling receptor binding activity. Involved in several processes, including positive regulation of calcium ion transport into cytosol; response to estradiol; and response to vitamin D. Located in external side of plasma membrane. Used to study septic arthritis and sialadenitis. Human ortholog(s) of this gene implicated in immunodeficiency 79. Orthologous to human CD4 (CD4 molecule). [provided by Alliance of Genome Resources, Apr 2022]
Cd4 Products (1)
| mRNA | Protein | Name |
|---|---|---|
| NM_012705.1 | NP_036837.1 | T-cell surface glycoprotein CD4 precursor |
| Molecular Function GO Annotation | Evidence | References | Source |
|---|---|---|---|
| enables immunoglobulin binding |
IDA
IDA: Inferred from direct assay
|
2338715 | RGD |
| enables protein kinase binding |
IPI
IPI: Inferred from physical interaction
|
1372996 | RGD |
| enables protein tyrosine kinase binding |
IDA
IDA: Inferred from direct assay
|
8959663 | RGD |
| enables signaling receptor binding |
IPI
IPI: Inferred from physical interaction
|
12115612 | RGD |
| Biological Process GO Annotation | Evidence | References | Source |
|---|---|---|---|
| involved in cellular response to ionomycin |
IEP
IEP: Inferred from expression pattern
|
25678251 | RGD |
| involved in positive regulation of T cell proliferation |
IMP
IMP: Inferred from mutant phenotype
|
15000837 | RGD |
| involved in positive regulation of calcium ion transport into cytosol |
IDA
IDA: Inferred from direct assay
|
8959663 | RGD |
| involved in response to estradiol |
IEP
IEP: Inferred from expression pattern
|
2478646 | RGD |
| involved in response to ethanol |
IEP
IEP: Inferred from expression pattern
|
8214423 | RGD |
| involved in response to methamphetamine hydrochloride |
IEP
IEP: Inferred from expression pattern
|
25678251 | RGD |
| involved in response to vitamin D |
IEP
IEP: Inferred from expression pattern
|
8759780 | RGD |
| Cellular Component GO Annotation | Evidence | References | Source |
|---|---|---|---|
| located in cell surface |
IDA
IDA: Inferred from direct assay
|
15474526 | RGD |
| located in external side of plasma membrane |
IDA
IDA: Inferred from direct assay
|
3159821 | RGD |
EXP: Inferred from Experiment
IDA: Inferred from direct assay
IPI: Inferred from physical interaction
IMP: Inferred from mutant phenotype
IGI: Inferred from genetic interaction
IEP: Inferred from expression pattern
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
T-cell surface glycoprotein CD4 |
|
|
Recombinant Cd4 Proteins
| Cat. No. | Product Name | Accession | Purity |
|---|---|---|---|
| HY-P72905 | CD4 Protein, Rat (HEK293, His) | P05540 (K28-T394) | ≥ 95%, as determined by reducing SDS-PAGE. |
Related Agents
- Approval
- Clinical Phase
- Pre-clinical Phase
Approval
Bioactive Molecules
(9)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-B0689A | Indinavir sulfate | 99.97% | Yes | |
| HY-B0426A | Olopatadine hydrochloride | 99.83% | Unkown | |
| HY-15440A | Fostemsavir | Inhibitor | 99.69% | Unkown |
| HY-B0689 | Indinavir | 99.96% | Yes | |
| HY-15440B | Fostemsavir Tris | Inhibitor | 99.78% | Unkown |
| HY-W062109 | Olopatadine | 98.94% | Unkown | |
| HY-135432 | Etrasimod arginine | Modulator | 99.86% | Unkown |
| HY-B0426AR | Olopatadine hydrochloride (Standard) | / | Unkown | |
| HY-B0689B | Indinavir sulfate ethanolate | / | Unkown |
Inhibitory Antibodies
(3)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-P99222 | Teplizumab | 99.73% | Unkown | |
| HY-108831 | Natalizumab | Inhibitor | 99.10% | Unkown |
| HY-P99028 | Ibalizumab | Inhibitor | 99.74% | Unkown |
Clinical Phase
Bioactive Molecules
(8)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase
|
|---|---|---|---|---|
| HY-105037 | Forigerimod | Inhibitor | / | Phase 3 |
| HY-148511 | Vidutolimod | 93.85% | Phase 3 | |
| HY-13644 | Gusperimus | / | Phase 3 | |
| HY-148808 | Zelasudil | Inhibitor | 99.48% | Phase 2 |
| HY-14135 | BMS 488043 | Inhibitor | / | Phase 2 |
| HY-15440 | Temsavir | Inhibitor | 98.70% | Phase 1 |
| HY-P0272 | Peptide T | Inhibitor | 98.68% | Phase 1 |
| HY-139780 | JNJ-61803534 | Inhibitor | 99.84% | Phase 1 |
Inhibitory Antibodies
(19)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase
|
|---|---|---|---|---|
| HY-P99266 | Zanolimumab | 99.33% | Phase 3 | |
| HY-P9998 | Semzuvolimab | Inhibitor | 97% | Phase 3 |
| HY-P991336 | Ordastobart | Agonist | 98% | Phase 3 |
| HY-P991214 | Tucotuzumab celmoleukin | 98.797% | Phase 3 | |
| HY-P9997 | Rosnilimab | Agonist | 99.19% | Phase 2 |
| HY-P99159 | Ivuxolimab | Activator | ≥99.0% | Phase 2 |
| HY-P99908 | Efineptakin alfa | Activator | 99.70% | Phase 2 |
| HY-P991069 | VRC-01 | Inhibitor | 99.805% | Phase 2 |
| HY-P990742 | Givastomig | Inhibitor | 98.556% | Phase 2 |
| HY-P990068 | Perenostobart | Inhibitor | 97.00% | Phase 2 |
| HY-P991424 | GSK2618960 | Inhibitor | 95.66% | Phase 2 |
| HY-P991246 | VRC01LS | Inhibitor | 98.78% | Phase 2 |
| HY-P99809 | Quavonlimab | Inhibitor | ≥99.0% | Phase 2 |
| HY-P99607 | Clenoliximab | Inhibitor | / | Phase 2 |
| HY-P99911 | Efizonerimod alfa | Agonist | 98.57% | Phase 1 |
| HY-P991307 | BND-35 | / | Phase 1 | |
| HY-P991436 | DF6002 | Activator | / | Phase 1 |
| HY-P991643 | MTRX1011A | Inhibitor | / | Phase 1 |
| HY-P991655 | AGS-009 | Inhibitor | / | Phase 1 |
Pre-clinical Phase
Bioactive Molecules
(148)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-150741C | ODN 2216 sodium | Agonist | 98.57% | Unkown |
| HY-P3719 | MOG(35-55) amide, mouse, rat | 99.88% | Unkown | |
| HY-110382 | Cyclic-di-GMP disodium | Activator | 98.78% | Unkown |
| HY-150741 | ODN 2216 | 98.57% | Unkown | |
| HY-126675A | AS2863619 | 98.02% | Unkown | |
| HY-143712 | Allolithocholic acid | 99.69% | Unkown | |
| HY-P2560 | LCMV GP (61-80) | 99.80% | Unkown | |
| HY-15898 | Y-320 | 99.03% | Unkown | |
| HY-120427 | Cosalane | Antagonist | 99.78% | Unkown |
| HY-107780B | Cyclic-di-GMP diammonium | Activator | 99.07% | Unkown |
| HY-134809 | Cyclotriazadisulfonamide | Inhibitor | 98.45% | Unkown |
| HY-P1684 | Peptide P60 | Inhibitor | 98.39% | Unkown |
| HY-P1066 | Apelin-17(human, bovine) | 98.71% | Unkown | |
| HY-Y0788 | Indoline | 99.89% | Unkown | |
| HY-160267 | iPAF1C | 99.59% | Unkown | |
| HY-164426 | HEI3090 | Activator | 99.00% | Unkown |
| HY-P1064 | Apelin-36(human) | 98.01% | Unkown | |
| HY-P1997 | Ferrichrome Iron-free | 98.5% | Unkown | |
| HY-W181026 | KLF10-IN-1 | 99.84% | Unkown | |
| HY-108136A | Bisindolylmaleimide X hydrochloride | 98.90% | Unkown | |
| HY-124750 | NecroX-7 | Inhibitor | 99.69% | Unkown |
| HY-126675 | AS2863619 free base | 99.87% | Unkown | |
| HY-119347 | Cirsilineol | Inhibitor | 98.0% | Unkown |
| HY-D0976 | NF279 | 98.5% | Unkown | |
| HY-P5425A | Tetanus Toxin (830–844) TFA | 96.13% | Unkown | |
| HY-P11303 | PADRE peptide | Ligand | 98.28% | Unkown |
| HY-P1745 | InsB (9-23) | Ligand | 98.98% | Unkown |
| HY-W060417 | iST2-1 | Inhibitor | 99.58% | Unkown |
| HY-P1065 | Apelin-36(rat, mouse) | 98.59% | Unkown | |
| HY-P6312 | ESAT6 Epitope | Ligand | 96.86% | Unkown |
| HY-P5453 | CFP10 (71–85) | 99.43% | Unkown | |
| HY-126037 | (±)-ML 209 | Antagonist | 98.14% | Unkown |
| HY-179089 | SBP-1750 | Inhibitor | 98.05% | Unkown |
| HY-W244412 | 2,5-Dioxopyrrolidin-1-yl 6-hydrazinylnicotinate hydrochloride | 95.0% | Unkown | |
| HY-107780 | Cyclic-di-GMP | Activator | 98.18% | Unkown |
| HY-105037A | Forigerimod TFA | Inhibitor | 99.88% | Unkown |
| HY-12465 | Z-Ile-Leu-aldehyde | 97.0% | Unkown | |
| HY-138115 | 7ß,27-Dihydroxycholesterol | Activator | 99.58% | Unkown |
| HY-14134 | BMS-378806 | Inhibitor | 98.94% | Unkown |
| HY-157793 | SMU-L11 | 99.64% | Unkown | |
| HY-165613 | Pam2Cys | 99.82% | Unkown | |
| HY-76648 | NBD-556 | Inhibitor | 99.57% | Unkown |
| HY-100039 | YYA-021 | Inhibitor | 98.96% | Unkown |
| HY-137640A | Sp-8-Br-cAMPS sodium | Agonist | 99.9% | Unkown |
| HY-162972 | PROTAC PD-L1 degrader-2 | Degrader | 95.23% | Unkown |
| HY-171860 | FC-14369 | Inhibitor | 97.85% | Unkown |
| HY-P1409A | ADWX 1 TFA | Inhibitor | 98.37% | Unkown |
| HY-P5917A | Vm24-toxin TFA | Inhibitor | 95.47% | Unkown |
| HY-Y0781S5 | Pyruvic acid-13C,d4 | 99.80% | Unkown | |
| HY-115488A | BNM-III-170 | Inhibitor | 98.48% | Unkown |
| HY-123312 | CK-548 | Inhibitor | 90% | Unkown |
| HY-146231 | SS47 | Degrader | / | Unkown |
| HY-148432 | FGF22-IN-1 | Inhibitor | 98.07% | Unkown |
| HY-162133 | MSA-2-Pt | / | Unkown | |
| HY-P1064A | Apelin-36(human) TFA | 99.42% | Unkown | |
| HY-16106S | Talazoparib-13C,d4 | 99.31% | Unkown | |
| HY-106055 | Murabutide | / | Unkown | |
| HY-108136 | Bisindolylmaleimide X | / | Unkown | |
| HY-110382S | Cyclic-di-GMP-13C20,15N10 disodium | Activator | / | Unkown |
| HY-111366 | CD12681 | Agonist | / | Unkown |
| HY-116282W | Dextran sulfate sodium salt (MW 6500-10000) | Inhibitor | / | Unkown |
| HY-119202 | (S)-BMS-378806 | / | Unkown | |
| HY-121820 | DMJ-I-228 | Inhibitor | / | Unkown |
| HY-123902 | Ophiobolin C | Inhibitor | / | Unkown |
| HY-126675G | AS2863619 (GMP) | / | Unkown | |
| HY-131675 | CH-100 | / | Unkown | |
| HY-134809A | Cyclotriazadisulfonamide hydrochloride | Inhibitor | / | Unkown |
| HY-137618B | Rp-dGTPαS | / | Unkown | |
| HY-143712R | Allolithocholic acid (Standard) | / | Unkown | |
| HY-143712S1 | Allolithocholic Acid-d4 | / | Unkown | |
| HY-144746 | PD-1/PD-L1-IN-26 | Inhibitor | / | Unkown |
| HY-15091 | Anisperimus | / | Unkown | |
| HY-154771S | Clopidogrelat-13C,d4 | / | Unkown | |
| HY-159123 | KHK-6 | Inhibitor | / | Unkown |
| HY-161255 | 3,4-DAA | Inhibitor | / | Unkown |
| HY-169335 | HIV-1 inhibitor-77 | Inhibitor | / | Unkown |
| HY-170948 | A2AR modulator-1 | Modulator | / | Unkown |
| HY-171859 | FC-14367 | Inhibitor | / | Unkown |
| HY-171862 | Nef ligand-2 | / | Unkown | |
| HY-173000 | STAT3-IN-40 | / | Unkown | |
| HY-176273 | RORγt inverse agonist 35 | Agonist | / | Unkown |
| HY-176755 | CCL-34 | Activator | / | Unkown |
| HY-177277 | HM5023507 | Inhibitor | / | Unkown |
| HY-179734 | PROTAC BRD4 Degrader-41 | / | Unkown | |
| HY-180563 | ADC 38 drug linker | / | Unkown | |
| HY-181599 | XAN-5 | / | Unkown | |
| HY-181663 | PJ27 | Inhibitor | / | Unkown |
| HY-181673 | ICD inducer-2 | / | Unkown | |
| HY-182369 | VA06 | Inhibitor | / | Unkown |
| HY-182674 | VGD020 | Inhibitor | / | Unkown |
| HY-182802 | Ferroptosis inducer-15 | / | Unkown | |
| HY-183784 | P2X7R antagonist-1 | / | Unkown | |
| HY-186205 | (Rac)-EGC-M5 | / | Unkown | |
| HY-B0094S3 | Artemisinin-13C,d4 | / | Unkown | |
| HY-B0426AS2 | Olopatadine-d6 hydrochloride | / | Unkown | |
| HY-B1473S2 | Serotonin-13C,D4 | / | Unkown | |
| HY-D3181 | CyGbPF | / | Unkown | |
| HY-D3334 | PE-CF594 | / | Unkown | |
| HY-N17465 | Dendronobiloside D | Inhibitor | / | Unkown |
| HY-P0272A | Peptide T TFA | Inhibitor | / | Unkown |
| HY-P10308 | [(Cys(Bzl)84,Glu(OBzl)85)]CD4 (81-92) | / | Unkown | |
| HY-P10382 | M133 peptide | / | Unkown | |
| HY-P10593 | Influenza A NP (383-391) (HLA-B27) | / | Unkown | |
| HY-P1065A | Apelin-36(rat, mouse) TFA | / | Unkown | |
| HY-P1066A | Apelin-17(human, bovine) TFA | / | Unkown | |
| HY-P10826 | PD-1/PD-L1 inhibitory peptide C8 | Inhibitor | / | Unkown |
| HY-P11090 | TpD | / | Unkown | |
| HY-P11122 | MSP-1 P2 | Activator | / | Unkown |
| HY-P11490 | DPMI-ω | Antagonist | / | Unkown |
| HY-P11802 | CD4 (81-92) (human) | Inhibitor | / | Unkown |
| HY-P2561 | Influenza Matrix Protein (61-72) | / | Unkown | |
| HY-P3554 | Carbomethoxycarbonyl-D-Pro-D-Phe-OBzl | Inhibitor | / | Unkown |
| HY-P4015 | VIP (1-12), human, porcine, rat, ovine | Ligand | / | Unkown |
| HY-P4902 | Retrocyclin-1 | Inhibitor | / | Unkown |
| HY-P5917 | Vm24-toxin | Inhibitor | / | Unkown |
| HY-P5930 | HOXB7 8–25 | / | Unkown | |
| HY-RS02245 | CD4 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-W005355S8 | Sodium 2-oxobutanoate-13C,d4 | 98.0% | Unkown | |
| HY-W006057AS14 | Sodium 3-methyl-2-oxobutanoate-13C,d4 | / | Unkown | |
| HY-W062109S | Olopatadine-d6 | / | Unkown | |
| HY-W387035 | D-α-Methyl DOPA | / | Unkown | |
| HY-W654058 | L-Arginine-13C,d4 dihydrochloride | / | Unkown | |
| HY-W795993 | TJU103 | Inhibitor | / | Unkown |
| HY-107780A | Cyclic-di-GMP sodium | Activator | / | Unkown |
| HY-115488 | BNM-III-170 free base | Inhibitor | / | Unkown |
| HY-117160S2 | 4-trans-Hydroxy glibenclamide-13C,d4 | / | Unkown | |
| HY-120630 | BMS-663749 | Inhibitor | / | Unkown |
| HY-123756 | NBD-10007 | Inhibitor | / | Unkown |
| HY-12926 | ST7612AA1 | / | Unkown | |
| HY-15440AS | Fostemsavir-d8 | Inhibitor | / | Unkown |
| HY-173077 | PD-L1/LpxC-IN-1 | Inhibitor | / | Unkown |
| HY-174625 | Human IL2 mRNA | 92.6% | Unkown | |
| HY-174725 | Human CXCR4 mRNA | / | Unkown | |
| HY-174754 | Human CCL28 mRNA | / | Unkown | |
| HY-174765 | Human CCL18 mRNA | / | Unkown | |
| HY-176280 | SARS-CoV-2-IN-115 | Inhibitor | / | Unkown |
| HY-181831 | XQ2 | Activator | / | Unkown |
| HY-181841 | TLR8 agonist 10 | / | Unkown | |
| HY-182376 | JRC-I-191 | Inhibitor | / | Unkown |
| HY-182690 | CK147 | Inhibitor | / | Unkown |
| HY-B0202S4 | Irbesartan-13C,d4 | / | Unkown | |
| HY-B0426AS | Olopatadine-d3 hydrochloride | / | Unkown | |
| HY-B0757 | Vitamin E nicotinate | Inhibitor | / | Unkown |
| HY-N5178 | Chloropeptin I | Inhibitor | / | Unkown |
| HY-RS16540 | Cd4 Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS22972 | Cd4 Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-W013677S1 | 4-Fluorobenzoic acid-13C,d4 | / | Unkown | |
| HY-110216 | 5J-4 | Inhibitor | 95% | Unkown |
Inhibitory Antibodies
(33)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-P990792 | Anti-Mouse CD4 Antibody (GK1.5) | Inhibitor | 99.16% | Unkown |
| HY-108831A | Natalizumab (Anti-CD49d) | Inhibitor | 99.71% | Unkown |
| HY-P990254 | Anti-Mouse CXCR3/CD183 Antibody (CXCR3-173) | Inhibitor | 99% | Unkown |
| HY-P990837 | Anti-IL-4 Antibody (MP4-25D2) | Inhibitor | ≥95.0% | Unkown |
| HY-P99141 | Anti-Mouse LAG-3 Antibody (C9B7W) | Inhibitor | 99% | Unkown |
| HY-P990839 | Anti-IFNγ Antibody (B133.5) | Inhibitor | ≥95.0% | Unkown |
| HY-P990242 | Anti-Mouse Galectin-9 Antibody (RG9-1) | Inhibitor | 95.64% | Unkown |
| HY-P99999 | Anti-Mouse CD4 Antibody (YTS 191) | Inhibitor | / | Unkown |
| HY-P991112 | Anti-Mouse CD8α Antibody (YTS169.4) | Inhibitor | 98.99% | Unkown |
| HY-P990175 | Anti-Mouse OX40L/CD134L Antibody (RM134L) | Inhibitor | 95.00% | Unkown |
| HY-P99680 | Keliximab | Inhibitor | 98.23% | Unkown |
| HY-P990861 | Anti-CD4 Antibody (OKT-4) | 95.00% | Unkown | |
| HY-P991110 | Anti-Mouse CD25 Antibody (7D4) | Inhibitor | ≥99.0% | Unkown |
| HY-P992030 | FB102 | 99.17% | Unkown | |
| HY-P990249 | Anti-Mouse DR5/CD262 Antibody (MD5-1) | Inhibitor | 99.20% | Unkown |
| HY-P990264 | Anti-Mouse CD70 Antibody (FR70) | Inhibitor | 95.00% | Unkown |
| HY-P990796 | Anti-Mouse IL-2 Antibody (S4B6-1) | Inhibitor | 96.97% | Unkown |
| HY-P991479 | Amtabafusp alfa | 99% | Unkown | |
| HY-P990135 | Anti-Rat CD4 Antibody (OX-38) | Inhibitor | 95.00% | Unkown |
| HY-P990304 | Anti-Mouse 4-1BBL/CD137L Antibody (TKS-1) | Inhibitor | ≥95.0% | Unkown |
| HY-P992063 | Anti-Mouse CD8α Antibody (YTS 105.18) | / | Unkown | |
| HY-P990353 | Anti-CD4 Antibody (TRX1) | Inhibitor | 99.28% | Unkown |
| HY-P990857 | Anti-CD54/ICAM-1 Antibody (R6-5-D6) | Inhibitor | / | Unkown |
| HY-P991762 | Anti-Rat CD4 Antibody (W3/25) | Inhibitor | / | Unkown |
| HY-P991824 | Anti-Mouse CD4 Antibody (YTS 177) | Inhibitor | / | Unkown |
| HY-P991892 | IT1208 | Inhibitor | / | Unkown |
| HY-P991892A | IT1208 (FUT8-KO) | Inhibitor | / | Unkown |
| HY-P992056 | Anti-Human/Mouse LY6E Antibody (9B12) | / | Unkown | |
| HY-P992434 | OSE-279 | / | Unkown | |
| HY-P992519 | PF-06940434 | / | Unkown | |
| HY-P99495 | Cedelizumab | Inhibitor | / | Unkown |
| HY-P99790 | Priliximab | / | Unkown | |
| HY-P991318 | AR20.5 | Inhibitor | / | Unkown |
Compound Screening Libraries
Virtual Screening
Customize Your Library
Drug Screening Service